Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy
Titel:
Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy
Auteur:
Felip, Enriqueta Hirsh, Vera Popat, Sanjay Cobo, Manuel Fülöp, Andrea Dayen, Charles Trigo, José M. Gregg, Richard Waller, Cornelius F. Soria, Jean-Charles Goss, Glenwood D. Gordon, James Wang, Bushi Palmer, Michael Ehrnrooth, Eva Gadgeel, Shirish M.